Floatz logo

ZIPRASIDONE

Schizoaffective Disorder

Centre for Addiction and Mental HealthSmall moleculePhase 4 / ApprovedDormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 4BBB
Risperdal
Lyndra Inc.
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB
Seroquel®
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

ZIPRASIDONE is also rated in:

Depression, BipolarDormant
BBB
Indicative ·
73 / 100
View asset →
psychotic disorderDormant
BB
Indicative ·
71 / 100
View asset →
Affective DisordersDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →